Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6

Yi-Long Wu,Yuankai Shi,Daniel Shao Weng Tan,Liu Xiaoqing,Ying Cheng,Jianying Zhou,Tong Tong An,You Lu,Bo Zhu,Chunxue Bai,Vanessa Q Passos,Yvonne Y Lau, Liao Xun,Li Zhang

Lung Cancer（2020）

引用 23|浏览44

暂无评分

摘要

•ASCEND-6 evaluated ceritinib in Chinese patients with advanced ALK+ NSCLC.•Ceritinib pharmacokinetics in ASCEND-6 was similar to that in ASCEND-1.•High response rate and durable clinical benefits were reported with ceritinib.•Safety profile was manageable and no new signals were detected.•Ceritinib had a positive benefit-to-risk ratio in Chinese patients.

查看译文

关键词

AE,ALK,ALT,AST,AUC0–24 h,BIRC,CI,Cmax,CNS,CR,CTCAE,DCR,DOR,FDA,ICH,IDCR,NSCLC,OIRR,ORR,OS,PFS,PK,PR,RECIST,SAE,T1/2,TKI,Tmax,TTR,US,Vz/F

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要